Company Filing History:
Years Active: 2011-2017
Title: The Innovative Contributions of Srinivas Gullapalli
Introduction
Srinivas Gullapalli is a notable inventor based in Navi Mumbai, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compositions that target pain management and cannabinoid receptor modulation. With a total of 4 patents to his name, his work reflects a commitment to advancing medical science.
Latest Patents
Gullapalli's latest patents include a pharmaceutical composition comprising a TRPA1 antagonist and an analgesic agent. This patent application focuses on a composition that utilizes a thienopyrimidinedione compound as a TRPA1 antagonist, aimed at treating pain in subjects. Another significant patent involves cannabinoid receptor ligands, which are novel modulators for cannabinoid receptors, specifically CB1 and CB2. This invention outlines the use of these modulators for treating various diseases and conditions influenced by cannabinoid receptors.
Career Highlights
Srinivas Gullapalli is currently associated with Glenmark Pharmaceuticals S.A., where he continues to innovate in the pharmaceutical sector. His work is characterized by a strong focus on developing effective treatments that leverage the latest scientific discoveries.
Collaborations
Gullapalli has collaborated with esteemed colleagues such as Meyyappan Muthuppalaniappan and Gopalan Balasubramanian, contributing to a dynamic research environment that fosters innovation.
Conclusion
Srinivas Gullapalli's contributions to pharmaceutical innovations demonstrate his dedication to improving healthcare through scientific advancements. His patents reflect a forward-thinking approach to pain management and cannabinoid research, marking him as a significant figure in the field.